PCSK9 Allosteric Ligands Modulate LDL Receptor Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate circulating levels of low-density lipoproteins (LDL) to treat hypercholesterolemia and related cardiovascular diseases, as they do not adequately address the interaction between PCSK9 and LDL receptors to regulate LDL-cholesterol levels.
Innovation Solution
The use of synthetic ligands and peptides that bind to specific sites on the PCSK9 protein, inducing conformational shifts to alter the interaction with LDL receptors, thereby modulating LDL-cholesterol levels by either increasing or decreasing their clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to modulate LDL levels, then treatment of hypercholesterolemia is attempted, but the methods fail to effectively regulate LDL-cholesterol levels due to inadequate addressing of PCSK9-LDL receptor interaction
Solution Approach 1:
The patent employs dynamic small molecule ligands that can bind to PCSK9 and induce conformational changes, allowing the system to adaptively modulate LDL receptor activity. The ligands can shift PCSK9 between active and inactive conformations, enabling dynamic control of LDL clearance based on therapeutic needs.
Solution Approach 2:
The invention utilizes small molecule ligands that induce conformational parameter changes in PCSK9 structure. By altering the conformational state of PCSK9 through ligand binding, the interaction affinity between PCSK9 and LDL receptors is modulated, thereby controlling LDL-cholesterol clearance rates.
2Object-affected harmful factors
If PCSK9 conformation is altered to increase LDL clearance, then high LDL-cholesterol levels are reduced, but LDL levels may become too low in conditions such as liver dysfunction
Solution Approach 1:
The patent describes dynamic conformational switching of PCSK9 between states that promote or inhibit LDL receptor binding. By controlling the conformational equilibrium through small molecule ligands, the system can dynamically adjust LDL clearance to prevent both excessive LDL reduction and maintain therapeutic benefits.
Solution Approach 2:
The invention enables feedback-controlled modulation of LDL levels by using ligands that respond to PCSK9 conformational states. The system can theoretically adjust PCSK9 activity based on circulating LDL levels, preventing both hypercholesterolemia and excessive LDL reduction that could harm liver function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise regulation of LDL-cholesterol levels, addressing both high and low levels to treat hypercholesterolemia and associated cardiovascular conditions by enhancing or inhibiting the binding affinity of LDL receptors, thus improving cardiovascular health.
Implementation Method 1
providing a PCSK9 protein, wherein the protein comprises a binding site that induces allosteric modulation and a low density lipoprotein receptor binding site
Implementation Method 2
binding the synthetic ligand to the binding site, wherein the synthetic ligand induces a conformation shift of the protein
Data Source
AI summary
This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 Da. Altering the conformation of PCSK9 affects the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for ligands which can raise LDL levels.